This article is mentioned in:

Introduction

Liver cancer is a leading cancer that occurs most commonly and is considered as the fourth most prevalent human tumor globally (1). Owing to increasing number of new liver cancer cases, it has become major public health challenge (2). In addition, weak prognosis of major hepatic malignancies results in the increase in the rate of mortality in primary liver cancer (1). Hepatocellular carcinoma (HCC) is the most common form of liver cancer, accounting for up to 90% of all primary hepatic malignancies (3). Despite advances in medical and surgical therapies, HCC remains one of the most common causes of cancer-related deaths worldwide since therapies do not always produce optimal patient outcomes (4). Therefore, more effective treatment methods of HCC are required, particularly certain specific targeted agents.

Traditional Chinese medicine (TCM) is an important therapy for liver cancer in China. Owing to its unique overall concept, treatment based on syndrome differentiation and abundant natural medicine resources, it has become a characteristic method throughout the entire process of liver cancer prevention and treatment (5,6). Ophiopogonin-B (OP-B) is a bioactive component from the root of Ophiopogon japonicus, which is widely used in TCM to treat pulmonary disease (7,8). In the last decade, an increasing number of studies reported the anticancer effect of OP-B on multiple malignant tumors, including lung, colon, gastric and ovarian cancer (7–10). It was previously demonstrated that OP-B induced HCC cell apoptosis and decreased invasion through inhibition of the JAK2/STAT3 signaling pathway, indicating the potential value of OP-B in treating HCC (11). In the present study, further in vivo and in vitro studies were performed to confirm whether OP-B exhibits an inhibitory effect on the malignant processes of HCC.

Protein tyrosine phosphatase 1B [PTP1B; encoded by protein tyrosine phosphatase non-receptor type 1 (PTPN1)] is an important member in PTP superfamily of proteins. PTPs catalyze phosphate monoesters hydrolysis on tyrosine residues; they are also known to act as signaling molecules to regulate a number of cellular processes, including cell growth, differentiation, mitotic cycle and oncogenic transformation (12). To date, PTP1B has been reported to be also involved in the development of obesity, diabetes, cancers and cardiovascular diseases (13). Recently, Xu et al (14) showed that PTPN1 was upregulated in HCC and its silencing suppressed proliferation and induced apoptosis of HCC cells. A similar result was reported by Yang et al (15), which suggested that downregulation of PTP1B inhibited HCC development. These results indicated an oncogenic role of PTP1B in HCC. Notably, it is predicted by SwissTargetPrediction online database (16) that PTPN1 (PTP1B) is one of the targets of OP-B (data not shown). Therefore, the present study aimed to investigate whether OP-B exhibited an inhibitory effect on the malignant process of HCC via targeting PTP1B.

Materials and methods

Cell culture and treatment

The human normal hepatocyte cell line HHL-5 and the HCC cell line MHCC97-H were obtained from the American Type Culture Collection. Both cell lines were cultured in DMEM (Sigma-Aldrich; Merck KGaA) supplemented with 10% fetal bovine serum (FBS; Wisent Biotechnology) and 1% penicillin-streptomycin (Sigma-Aldrich; Merck KGaA) in an incubator with 5% CO2 at 37°C. For OP-B treatment, cells were cultured in DMEM containing different concentrations (5, 10, 20 and 40 µM) of OP-B (purity >97%; Shanghai Yuanye Bio-Technology Co., Ltd.) for 24 h as previously described (8,11,17,18). Cells cultured in normal DMEM without OP-B were used as a control.

Cell transfection

A PTP1B overexpression vector (Ov-PTP1B) was constructed by cloning human PTP1B cDNA into the pcDNA3.1 vector (Thermo Fisher Scientific, Inc.). Empty pcDNA3.1 vector was used as negative control (Ov-NC). MHCC97-H cells were grown in six-well plates and subsequently transfected with 2 µg of either vector using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) at 37°C for 24 h according to the manufacturer's protocol. At 48 h post-transfection, monoclonal cells were then selected and examined for PTP1B overexpression.

Xenograft tumor model

A total of 15 male BALB/c nude mice (age, 4–5 weeks; 15–20 g; Shanghai Laboratory Animal Center) were maintained under specific pathogen-free conditions at room temperature under a controlled 12/12 h light/dark cycle, and received food and water ad libitum. The animal study protocol was approved by the Ethics Committee of Suzhou Hospital of Integrated Traditional Chinese and Western Medicine (Suzhou, China; approval no. 20180901). To establish the HCC xenograft model, MHCC97-H cells (2×106 cells/200 µl) were subcutaneously injected into the right flank of the nude mice. After six days, mice were treated by oral gavage with normal saline (control group; n=5), 15 mg/kg OP-B (OP-B 15 mg/kg group; n=5) or 75 mg/kg OP-B (OP-B 75 mg/kg group; n=5) once a day for 21 days, as previously described (8,17,18). Mouse body weight and tumor volume were recorded every 7 days; at 21 days post-treatment, the mice were sacrificed by cervical dislocation under anesthesia with 1% sodium pentobarbital (50 mg/kg intraperitoneally). Tumor volumes for each mouse were calculated as follows: Tumor volume=1/2 × length × width2.

Immunohistochemistry (IHC)

Xenografted tumor tissues were fixed with 4% paraformaldehyde at 4°C for 12 h and embedded in paraffin. After being deparaffinized with xylene and rehydrated with a descending ethanol series, slides (3 µm thickness) were stained with the IHC Assay Kit (cat. no. KGOS300; Nanjing KeyGen Biotech Co., Ltd.) according to the manufacturer's protocol and then incubated at 4°C overnight with the following primary antibodies purchased from Abcam: Anti-Ki67 (1:1,000; cat. no. ab15580), anti-CD31 (1:50; cat. no. ab28364) and anti-VEGFA (1:200; cat. no. ab52917). Secondary antibody goat anti-rabbit IgG (1:1,000; cat. no. ab6721; Abcam) was applied at room temperature for 2 h. Images of the tissue sections were then captured with a fluorescence microscope (DMi8; Leica Microsystems GmbH; ×200 magnification).

Cell viability

Cell Counting Kit-8 (CCK8; Beyotime Institute of Biotechnology) was used to measure cell viability. Briefly, cells were seeded into 96-well plates at a density of 1,000 cells/well at 37°C for 24 h. After treatment with different concentrations of OP-B (0, 5, 10, 20 and 40 µM) at 37°C for 24 h, cells were incubated with 10 µl of CCK-8 solution at 37°C for 2 h. The optical density was calculated at 450 nm using a microplate reader (Model550; Bio-Rad Laboratories, Inc.).

Colony formation

For the colony formation assay, 1×103 MHCC97-H cells were cultivated in six-well plates in a 37°C incubator with 5% CO2. After 14 days, cell colonies were fixed with 95% alcohol at room temperature for 30 min and stained with 0.1% crystal violet at room temperature for 30 min (Sigma-Aldrich; Merck KGaA). Images were captured with a light microscope (Nikon Corporation; ×200 magnification) and colonies were counted using ImageJ software (version 1.8.0; National Institutes of Health).

TUNEL staining

According to the manufacturer's protocol, MHCC97-H cell apoptosis was analyzed using TUNEL Assay kit (Abcam). Briefly, cells were fixed in 4% paraformaldehyde solution for 30 min at room temperature, treated with 0.2% Triton X-100 for 5 min at room temperature, washed twice in PBS at room temperature, and labeled with fluorescein-12-dUTP using terminal deoxynucleotidyl transferase for 2 h at room temperature. Subsequently, cell nuclei were stained with 5 µg/ml DAPI at room temperature for 3 min. All images were obtained using a fluorescence microscope (DMi8; Leica Microsystems GmbH; ×200 magnification).

Wound healing assay

Briefly, MHCC97-H cells were seeded in a six-well plate at a density of 5×105 cells/well in DMEM. When the cells were ~80% confluent, scratches were made in the middle of slides using a sterile 10-µl pipette tip. After incubation for another 48 h with or without 20 µM OP-B in serum-free DMEM at 37°C, images were captured to estimate closure of the gap using a light microscope (Nikon Corporation; ×200 magnification). Migration distance was evaluated using ImageJ software (version 1.8.0; National Institutes of Health) and calculated as follows: Migration distance=(width of gap at 0 h-width of gap at 48 h)/width of gap at 0 h. Data are shown as relative migration distance by normalization to the control group.

Transwell invasion assay

The invasive ability of MHCC97-H cells was evaluated by the Biocoat invasion assay kit (Corning, Inc.) strictly following the manufacturer's protocol. Firstly, 5×105 cells per well were plated in the upper chamber followed by treatment with 20 µM OP-B or not. After 12 h of treatment, the cells in the upper chamber were incubated with serum-free DMEM medium, whereas media supplemented with 10% FBS was placed at the lower chamber. After 48 h, the invasive cells at the lower chamber were stained with 0.1% crystal violet at room temperature and observed using an optical light microscope (Leica Microsystems GmbH; ×200 magnification).

Tube formation assay

Matrigel (BD Biosciences) was thawed at 4°C, pipetted into 96-well plates and allowed to polymerize at 37°C for 1 h. Cells (1×104 per well) were suspended in DMEM containing 0 or 20 µM OP-B and seeded onto the Matrigel. After incubation for 24 h at 37°C, tube formation was analyzed by counting nodes and measuring total tube numbers using ImageJ software (version 1.8.0; National Institutes of Health).

Reverse transcription-quantitative PCR (RT-qPCR)

Total RNA was extracted using TRIzol® (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol, and then reverse transcribed into cDNA using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to the manufacturer's protocol. SYBR-Green Supermix (Takara Biotechnology Co., Ltd.) was used for qPCR in a 10 µl reaction volume on the Roche Light Cycler R480 System (Roche Diagnostics). The following thermocycling conditions were used for the qPCR: Initial denaturation at 95°C for 30 sec; followed by 40 cycles of denaturation at 95°C for 10 sec, annealing at 60°C for 20 sec and extension at 70°C for 10 sec. Target gene expression levels were analyzed using the 2−ΔΔCq (19) method and normalized to GAPDH. The primers used for RT-qPCR were as follows: PTP1B forward, 5′-CCAGCCAAAGGGGAGCCGTC-3′ and reverse, 5′-CTATGTGTTGCTGTTGAACA-3′; and GAPDH forward, 5′-AATGGGCAGCCGTTAGGAAA-3′ and reverse, 5′-GCGCCCAATACGACCAAATC-3′.

Western blot assay

Total protein was extracted from cells or tumor tissues by RIPA lysis buffer (Beyotime Institute of Biotechnology). Total protein was quantified using a BCA Kit (Beyotime Institute of Biotechnology), mixed with 5X sample buffer and boiled at 95°C for 5 min. Equal amounts (40 µg) of protein lysate per sample were separated on 10% gels using SDS-PAGE and transferred onto the PVDF membranes. After blocking with 5% skimmed milk for 2 h at room temperature, membranes were incubated with primary antibodies at 4°C overnight and secondary antibodies (goat anti-rabbit IgG HRP; 1:10,000; cat. no. ab6721; Abcam) at room temperature for 2 h. An enhanced chemiluminescence (ECL) detection kit (Amersham; Cytiva) was used to visualize the protein bands. Band intensity was semi-quantified by ImageJ software (v1.8.0; National Institutes of Health). Primary antibodies (all from Abcam) included: anti-PTP1B (1:1,000; cat. no. ab252928), anti-Bcl-2 (1:1,000; cat. no. ab32124), anti-Bax (1:5,000; cat. no. ab32503), anti-cleaved caspase 3 (1:500; cat. no. ab32042), anti-caspase-3 (1:1,000; cat. no. ab184787), anti-cleaved poly ADP-ribose polymerase (PARP; 1:5,000; cat. no. ab32064), anti-PARP (1:5,000; cat. no. ab191217), anti-E-cadherin (1:10,000; cat. no. ab40772), anti-N-cadherin (1:10,000; cat. no. ab76011), anti-Vimentin (1:1,000; cat. no. ab45939), anti-VEGFA (1:10,000; cat. no. ab52917), anti-phosphorylated (p)-phosphatidylinositol 3 kinase (PI3K; 1:1,000; cat. no. ab191606), anti-total (t)-PI3K (1:1,000; cat. no. ab278545), anti-p-AKT (1:1,000; cat. no. ab38449), anti-t-AKT (1:1,000; cat. no. ab8805), anti-p-adenosine 5′-monophosphate-activated protein kinase (AMPK; 1:1,000; cat. no. ab109402), anti-t-AMPK (1:1,000; cat. no. ab214425) and anti-GAPDH (1:10,000; cat. no. ab181602).

Statistical analysis

Data are expressed as the mean ± standard deviation. One-way ANOVA followed by Tukey's post hoc test was used for analysis between multiple groups. Calculations were performed using GraphPad Prism software (version 5.0; GraphPad Software, Inc.). P<0.05 was considered to indicate a statistically significant difference.

Results

OP-B inhibits tumor growth and PTP1B expression in HCC xenografted mice

The anticancer effects of OP-B on HCC were first investigated in vivo. HCC xenografts were injected into mice (Fig. 1A) that were subsequently treated orally with 0, 15 or 75 mg/kg OP-B. Tumor volume and mouse body weight were examined for 21 days (Fig. 1B). The tumors were excised (Fig. 1C) and the final tumor weight and the tumor/body weight ratio were measured. (Fig. 1D), which were significantly reduced in mice treated with both 15 and 75 mg/kg OP-B compared with the control mice. Additionally, it was observed from IHC results that the expression level of Ki67 (Fig. 1E), CD31 (Fig. 1F) and VEGFA (Fig. 1G) in HCC tumor tissues of the xenografted mice was markedly decreased upon OP-B (15 and 75 mg/kg) administration compared with the control mice. In addition, the mRNA and protein expression levels of PTP1B in tumor samples of xenograft mice model was significantly inhibited by OP-B (Fig. 1H and I, respectively). These results showed that OP-B exerted anticancer effect on HCC in vivo.

Figure 1. Effect of OP-B on HCC progression and PTP1B expression in vivo. (A) HCC xenograft mice were treated with normal saline, or with 15 or 75 mg/kg OP-B for 21 days. (B) Body weight and tumor volumes were recorded every 7 days. (C) HCC tumors in different groups were removed from xenograft model and (D) weighed and the tumor/body weight was also calculated. The expression of Ki67 (E), CD31 (F) and VEGFA (G) in tumor samples of HCC xenograft mice were detected by IHC. (H) mRNA and (I) protein expression levels of PTP1B in tumor samples of HCC xenograft mice were measured by reverse transcription-quantitative PCR and western blot assays, respectively. *P<0.05, **P<0.01 and ***P<0.001 vs. control. HCC, hepatocellular carcinoma; IHC, immunohistochemistry; OP-B, ophiopogonin-B; PTP1B, protein tyrosine phosphatase 1B.

OP-B reduces cell viability and PTP1B expression in HCC cells

To validate the effect of OP-B on HCC and PTP1B expression in vitro, HHL-5 human normal hepatocyte and MHCC97-H HCC cells were exposed to different concentrations of OP-B (5, 10, 20 and 40 µM) for 24 h, then cell viability was measured. As revealed in Fig. 2A, OP-B treatment did not cause significant effect on HHL-5 cell viability, but significantly reduced MHCC97-H cell viability in a concentration-dependent manner. In addition, both the mRNA and the protein expression levels of PTP1B were significantly downregulated by OP-B (Fig. 2B and C, respectively).

Figure 2. Effect of OP-B on PTP1B expression in hepatocellular carcinoma cells. (A) HHL-5 and MHCC97-H cells were exposed to different concentrations of OP-B for 24 h, then cell viability was measured by Cell Counting Kit-8 assay. MHCC97-H cells were treated with different concentrations of OP-B for 24 h, then PTP1B (B) mRNA and (C) protein expression levels were evaluated. MHCC97-H cells were either transfected with Ov-PTP1B or empty vector, then the overexpression efficiency was verified by (D) reverse transcription-quantitative PCR and (E) western blot assays. *P<0.05, **P<0.01 and ***P<0.001 vs. control. NC, negative control; OP-B, ophiopogonin-B; Ov, overexpression vector; PTP1B, protein tyrosine phosphatase 1B.

Subsequently, PTP1B was overexpressed in MHCC97-H cells by transfection of Ov-PTP1B vector and then the overexpression efficiency was confirmed by RT-qPCR and western blotting (Fig. 2D and E, respectively).

Decreased PTP1B expression may be responsible for the anticancer effect of OP-B on HCC

To observe the effect of OP-B on the malignant processes of HCC, MHCC97-H cells overexpressing PTP1B were treated with 20 µM OP-B, then cell proliferation, apoptosis, migration, invasion and angiogenesis were evaluated. As revealed in Fig. 3A, OP-B significantly reduced cell viability compared with the untreated control group, whereas OP-B + Ov-PTP1B treatment significantly enhanced the cell viability compared with the OP-B + Ov-NC group. These results indicated that the inhibitory effect of OP-B on HCC cell viability was reversed by PTP1B overexpression. Furthermore, OP-B markedly suppressed the colony formation compared with control MHCC97-H cells, whereas PTP1B overexpression markedly reduced this effect (Fig. 3B). TUNEL staining revealed that apoptosis was significantly increased upon OP-B treatment compared with the control group, and PTP1B overexpression reduced the level of apoptosis compared with OP-B + Ov-NC (Fig. 3C). Consistently, OP-B treatment resulted in decreased protein expression of Bcl-2, but increased expression levels of Bax, cleaved caspase 3 and cleaved PARP, suggesting the induction of cell apoptosis (Fig. 3D). However, PTP1B overexpression caused a reverse effect on the expression of these proteins in OP-B-treated cells (Fig. 3D).

Figure 3. Effect of OP-B and PTP1B overexpression on hepatocellular carcinoma cell proliferation and apoptosis. MHCC97-H cells were transfected with Ov-PTP1B or OV-NC and subsequently treated with 20 µM OP-B. (A) Cell viability was measured by Cell Counting Kit-8 assay. (B) Colony formation was performed to observe cell proliferation. (C) TUNEL staining was used to assess apoptosis. (D) Protein expression levels of apoptosis-related proteins were detected by western blotting; GAPDH was used as the loading control. ***P<0.001 vs. control; ##P<0.01 and ###P<0.001 vs. OP-B + Ov-NC. NC, negative control; OP-B, ophiopogonin-B; Ov, overexpression vector; PTP1B, protein tyrosine phosphatase 1B.

Results from wound healing, invasion and tube formation assays demonstrated that OP-B significantly inhibited MHCC97-H cell migration, invasion and angiogenesis compared with untreated control cells (Fig. 4A-C, respectively). By contrast, OP-B + Ov-PTP1B treatment significantly increased these processes compared with OP-B + Ov-NC group (Fig. 4A-C). In addition, OP-B treatment significantly increased E-cadherin expression but decreased N-cadherin, Vimentin and VEGFA expression (Fig. 4D), whereas PTP1B overexpression reversed the effect on the expression levels of these proteins caused by OP-B.

Figure 4. Effect of OP-B treatment and PTP1B overexpression on migration, invasion and angiogenesis of hepatocellular carcinoma cells. MHCC97-H cells were transfected with Ov-PTP1B or OV-NC and subsequently treated with 20 µM OP-B. (A) Cell migration was determined by wound healing assay. (B) Transwell assay was performed to observe cell invasion. (C) Tube formation assay was used to assess cell angiogenesis. (D) Protein expression levels of E-cadherin, N-cadherin, Vimentin and VEGFA were detected by western blot analysis. ***P<0.001 vs. control; ##P<0.01 and ###P<0.001 vs. OP-B + Ov-NC. NC, negative control; OP-B, ophiopogonin-B; Ov, overexpression vector; PTP1B, protein tyrosine phosphatase 1B.

OP-B inactivates the PI3K/AKT signaling and activates AMPK signaling by reducing PTP1B expression

To uncover the underlying related signaling mechanism of OP-B, the expression of the PI3K/AKT and AMPK signaling pathways was detected. As demonstrated in Fig. 5, MHCC97-H cells showed decreased p/t-PI3K and p/t-AKT expression levels as well as increased p/t-AMPK expression in response to OP-B treatment. Conversely, when compared with OP-B + Ov-NC, OP-B + Ov-PTP1B treatment significantly upregulated p/t-PI3K and p/t-AKT expression levels and downregulated p/t-AMPK expression. These data indicated that OP-B may inhibit PI3K/AKT activation and activate the AMPK signaling, which is supported by the data showing that these effects were blocked by PTP1B overexpression.

Figure 5. Effect of OP-B and PTP1B overexpression on PI3K/AKT and AMPK signaling in hepatocellular carcinoma cells. MHCC97-H cells were transfected with Ov-PTP1B or OV-NC and subsequently treated with 20 µM OP-B, then the protein expression levels of components of the PI3K/AKT and AMPK signaling pathways were detected by western blotting. ***P<0.001 vs. control; ###P<0.001 vs. OP-B + Ov-NC. NC, negative control; OP-B, ophiopogonin-B; Ov, overexpression vector; PTP1B, protein tyrosine phosphatase 1B.

Discussion

OP-B is a natural active compound extracted from the TCM Ophiopogon japonicus root, which was found to exert inhibitory effect on non-small cell lung cancer cell lines (20). In the present study, OP-B was demonstrated to inhibit HCC development both in vitro and in vivo. Further experiments indicated that OP-B may exert its anticancer effect on HCC by targeting PTP1B and regulating the PI3K/AKT and AMPK signaling pathways.

Natural compounds from TCM have been revealed to exert remarkable effects in the treatment of HCC (21–24). For example, PHY906 has been reported to reduce the adverse effects of capecitabine in advanced HCC patients in a phase I/II clinical study (25). These studies reflected the satisfactory curative effect and huge potential of TCM in the treatment of HCC. In the present study, 15 and 75 mg/kg OP-B was selected for treating HCC-xenografted mice by oral gavage according to previous studies (8,17,18). OP-B at these two doses had no toxic effect on mice; it did not affect the mental state, life activity and weight gain of rats with the exception of 75 mg/kg OP-B, which significantly reduced body weight at 21 days post-treatment and this may due to the significant reduction in tumor weight caused by 75 mg/kg OP-B treatment. Additionally, it was found that in HCC xenograft tumors, OP-B effectively inhibited the growth of tumor and the expression of Ki67, CD31 and VEGFA. In in vitro experiments, OP-B did not affect the cell viability of normal hepatocyte HHL-5, but significantly impaired that of the HCC cell line MHCC97-H. Meanwhile, it was observed that 40 µM OP-B reduced the cell viability of MHCC97-H to less than 50%, indicating the excessive toxicity caused by 40 µM OP-B. Thus 5, 10 and 20 µM OP-B was utilized for subsequent functional analysis and results showed that treatment with OP-B significantly suppressed proliferation, migration, invasion and angiogenesis, but induced apoptosis of HCC cells. In addition, the expression of E-cadherin was enhanced and that of N-cadherin, vimentin and VEGFA was decreased upon OP-B treatment. Ki67 is a well-known cell proliferation marker; CD31 is a well-known marker of endothelial cells and a key factor for adhesion and accumulation of platelets (26); VEGFA is the key regulator of angiogenesis during the growth of solid tumors (26). Loss of E-cadherin expression results in loss of contact inhibition and is associated with increased cell motility and advanced stages of cancer (27); N-cadherin and Vimentin are recognized as a markers for epithelial-mesenchymal transition (EMT) (28). Consistently, the in vivo and in vitro results of the present study demonstrated the anticancer effect of OP-B on HCC.

To uncover the mechanism through which OP-B exert its anticancer effect, its potential downstream targets were predicted using SwissTargetPrediction online database and PTP1B was identified as one of the targets of OP-B (data not shown). Notably, the participation of PTP1B in liver cancer initiation and progression has been previously reported (15,29,30). Results from the present study showed that OP-B reduced the expression of PTP1B both in HCC tumor tissues and in cells in a concentration-depend manner. It was therefore speculated that OP-B may suppress the progression of HCC by targeting PTP1B. Further functional analysis revealed that overexpression of PTP1B significantly reversed the effect of OP-B treatment on malignant processes of HCC cells, indicating that PTP1B downregulation may be responsible for the anticancer effect of OP-B on HCC.

Finally, the mechanisms underlying the actions of OP-B/PTP1B in HCC were uncovered. Jin et al (31) reported that PTP1B promoted the progression of glioma by activating the MAPK/ERK and PI3K/AKT pathways. Xu et al (32) demonstrated that inhibition of PTP1B blocked pancreatic cancer progression by targeting the PKM2/AMPK/mTOC1 pathway. OP-B was also found to inhibit the PI3K/Akt signaling pathway in non-small cell lung cancer cells (20). The PI3K/AKT pathway had been extensively studied and found to be commonly activated in human cancer. Inhibition of this pathway leads to regression of human tumors (33). AMPK signaling is generally considered a key effector that mediates the tumor-suppressive function of liver kinase B1 (34). The inhibition of PI3K/AKT pathway or the activation of AMPK pathway has been found to inhibit proliferation, migration, invasion and EMT of cancer cells by regulating the expression of related markers such as Ki67, CD31, VEGFA, E-cadherin, N-cadherin and Vimentin (35–37). In the present study, OP-B inhibited the phosphorylation of PI3K/AKT and enhanced the phosphorylation of AMPK, whereas PTP1B overexpression reversed the effect of OP-B on the PI3K/AKT and AMPK signaling pathways. Although the present results were opposite with certain previous studies (38,39), which showed that PTP1B inhibited the phosphorylation of PI3K/AKT signaling, the effect of PTP1B on PI3K/AKT and AMPK phosphorylation in cancer cells was demonstrated for the first time, to the best of our knowledge. Further studies are required to investigate whether it is due to the particularity of cancer cells compared with normal healthy cells that led to this opposite finding. Combined with previous findings (11), it was demonstrated that OP-B could indeed suppress the malignant processes of HCC through regulating multiple pathways. However, the involvement of the PI3K/AKT and AMPK signaling pathways needs further validation using an agonist or antagonist of these two pathways. Whether OP-B could inhibit HCC through regulating other pathways involved in HCC progression, such as TGF-β, mTOR and Wnt/β-catenin signaling pathways (40–42) needs to be elucidated in future studies.

Collectively, the present study demonstrated that OP-B suppressed the progression of HCC both in vivo and in vitro through targeting PTP1B. Additionally, the PI3K/AKT and AMPK signaling pathways may be involved in this effect. These results may provide insight into the underlying mechanism involved in the antitumor effects of OP-B on HCC and may support the application of OP-B in a clinical setting.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Basic Research on Medical and Health Application of Suzhou Science and Technology Program (grant no. sys2018003).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

JS and YZ conceived and designed the study. FY, QG and HT performed the experiments. FY and QG analyzed and interpreted the data. JS and YZ drafted the manuscript and revised it for critically important intellectual content. JS and YZ confirm the authenticity of all the raw data. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

The animal study protocol was approved by the Ethics Committee of Suzhou Hospital of Integrated Traditional Chinese and Western Medicine (Suzhou, China; approval no. 20180901).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References